文献速递眼底病与葡萄膜炎

遗传变异与年龄相关性黄斑变性抗VEGF治疗反应的关联

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

这项多中心全基因组关联研究纳入2058例新生血管性年龄相关性黄斑变性(nAMD)患者,所有患者接受3次每月抗VEGF注射。研究发现常见遗传变异对治疗反应变异的贡献有限,而C10orf88和UNC93B1基因的罕见变异与更差的治疗反应相关,这些结果需在其他队列中进一步验证。

要点

  • 常见变异对nAMD抗VEGF治疗反应变异的贡献有限。
  • CCT3基因rs12138564与更好的治疗结果名义相关(P=1.38×10-5)。
  • C10orf88和UNC93B1罕见变异与更差治疗反应相关,需进一步验证。

核心结论

  • 常见遗传变异对nAMD治疗反应变异的贡献有限。
  • C10orf88和UNC93B1基因的罕见蛋白改变变异与抗VEGF治疗更差反应相关,但需其他队列验证。

研究设计与样本

  • 多中心全基因组关联研究,发现阶段纳入678例nAMD患者,验证阶段额外1380例nAMD患者进行选定常见变异基因分型。
  • 所有参与者接受3次每月贝伐珠单抗或雷珠单抗注射。
  • 共纳入2058例患者,1210例(58.8%)为女性,平均(SD)年龄78(7.4)岁,发现队列及多数验证队列患者为欧洲血统。

主要发现

  • 平均(SD)基线视力为51.3(20.3)ETDRS字母评分,3次每月注射负荷剂量后平均(SD)视力变化为增加5.1(13.9)ETDRS字母。
  • 全基因组常见单变异分析发现5个独立位点P值小于10×10-5;复制及荟萃分析后,CCT3基因rs12138564与更好治疗结果名义相关(ETDRS字母增加1.7;β=0.034;SE=0.008;P=1.38×10-5)。
  • 罕见变异基因水平分析显示C10orf88(P=4.22×10-7)和UNC93B1(P=6.09×10-7)基因全基因组显著关联,均导致更差治疗结果。
  • 携带C10orf88和UNC93B1罕见变异患者抗VEGF治疗3个月后分别平均(SD)视力丢失30.6(17.4)和26.5(13.8)ETDRS字母。

关键数值与推荐

  • 主要结局为3次每月抗VEGF注射负荷剂量后视力较基线的变化。

临床怎么用

  • 识别药物遗传学关联可能帮助临床医生理解nAMD治疗反应变异的机制,并为个性化治疗铺路。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Visual acuity (VA) outcomes differ considerably among patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) drugs. Identification of pharmacogenetic associations may help clinicians understand the mechanisms underlying this variability as well as pave the way for personalized treatment in nAMD. OBJECTIVE: To identify genetic factors associated with variability in the response to anti-VEGF therapy for patients with nAMD. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter genome-wide association study, 678 patients with nAMD with genome-wide genotyping data were included in the discovery phase; 1380 additional patients with nAMD were genotyped for selected common variants in the replication phase. All participants received 3 monthly injections of bevacizumab or ranibizumab. Clinical data were evaluated for inclusion/exclusion criteria from October 2014 to October 2015, followed by data analysis from October 2015 to February 2016. For replication cohort genotyping, clinical data collection and analysis (including meta-analysis) was performed from March 2016 to April 2017. MAIN OUTCOMES AND MEASURES: Change in VA after the loading dose of 3 monthly anti-VEGF injections compared with baseline. RESULTS: Of the 2058 included patients, 1210 (58.8%) were women, and the mean (SD) age across all cohorts was 78 (7.4) years. Patients included in the discovery cohort and most of the patients in the replication cohorts were of European descent. The mean (SD) baseline VA was 51.3 (20.3) Early Treatment Diabetic Retinopathy Study (ETDRS) score letters, and the mean (SD) change in VA after the loading dose of 3 monthly injections was a gain of 5.1 (13.9) ETDRS score letters (ie, 1-line gain). Genome-wide single-variant analyses of common variants revealed 5 independent loci that reached a P value less than 10 × 10-5. After replication and meta-analysis of the lead variants, rs12138564 located in the CCT3 gene remained nominally associated with a better treatment outcome (ETDRS letter gain, 1.7; β, 0.034; SE, 0.008; P = 1.38 × 10-5). Genome-wide gene-based optimal unified sequence kernel association test of rare variants showed genome-wide significant associations for the C10orf88 (P = 4.22 × 10-7) and UNC93B1 (P = 6.09 × 10-7) genes, in both cases leading to a worse treatment outcome. Patients carrying rare variants in the C10orf88 and UNC93B1 genes lost a mean (SD) VA of 30.6 (17.4) ETDRS score letters (ie, loss of 6.09 lines) and 26.5 (13.8) ETDRS score letters (ie, loss of 5.29 lines), respectively, after 3 months of anti-VEGF treatment. CONCLUSIONS AND RELEVANCE: We propose that there is a limited contribution of common genetic variants to variability in nAMD treatment response. Our results suggest that rare protein-altering variants in the C10orf88 and UNC93B1 genes are associated with a worse response to anti-VEGF therapy in patients with nAMD, but these results require further validation in other cohorts.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lorés-Motta L, Riaz M, Grunin M, et al. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. JAMA Ophthalmol. 2018. PMID: 29852030. doi:10.1001/jamaophthalmol.2018.2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。